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PolyMorphine provides extended analgesic-
like effects in mice with spared nerve injury
Neil C Lax1, Renxun Chen2, Sarah R Leep1, Kathryn E Uhrich2,4,
Lei Yu3 and Benedict J Kolber1
Abstract
Morphine is a well-characterized and effective analgesic commonly used to provide pain relief to patients suffering from both
acute and chronic pain conditions. Despite its widespread use and effectiveness, one of the major drawbacks of morphine is
its relatively short half-life of approximately 4 h. This short half-life often necessitates multiple administrations of the drug
each day, which may contribute to both dependence and tolerance to morphine. Here, we tested the analgesic properties of
a new polymer form of morphine known as PolyMorphine. This polymer has monomeric units of morphine incorporated into
a poly(anhydride-ester) backbone that has been shown to hydrolyze into free morphine in vitro. Using an animal model of
chronic pain, the spared nerve injury surgery, we showed that PolyMorphine is able to block spared nerve injury-induced
hypersensitivity in mice for up to 24-h post-administration. Free morphine was shown to only block spared nerve injury-
induced hypersensitivity for up to 2-h post-injection. PolyMorphine was also shown to act through the mu opioid receptor
due to the ability of naloxone (a mu opioid receptor antagonist) to block PolyMorphine-induced analgesia in spared nerve
injury animals pretreated with PolyMorphine. Additionally, we observed that PolyMorphine causes similar locomotor and
constipation side effects as free morphine. Finally, we investigated if PolyMorphine had any effects in a non-evoked pain assay,
conditioned place preference. Pretreatment of spared nerve injury mice with PolyMorphine blocked the development of
conditioned place preference for 2-methyl-6-(phenylethynyl)pyridine (MPEP), a short-lasting mGluR5 antagonist with analge-
sic-like properties. Free morphine does not block the development of preference for MPEP, suggesting that PolyMorphine has
longer lasting analgesic effects compared to free morphine. Together, these data show that PolyMorphine has the potential to
provide analgesia for significantly longer than free morphine while likely working through the same receptor.
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Introduction
Morphine is one of the most commonly used and most
well-known analgesics in both humans and animals.1
Morphine is an agonist of the mu opioid receptor
(MOR) and binds to this receptor 3.4 and 10 times
stronger than the other opioid receptor subtypes, the
kappa and delta opioid receptors, respectively.2 With
the activation of the MOR, morphine inhibits the release
of neurotransmitter by decreasing calcium entry at
presynaptic nerve endings and induces hyperpolarization
in the post-synaptic cell at a number of CNS sites and
on primary afferent neurons.3 These mechanisms are
believed to cause the analgesic effects of morphine.
Yet, despite its success in blocking pain, a major
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drawback to morphine use is its relatively short half-life
of approximately 4 h.4 In vivo, morphine is quickly dis-
tributed5 and subsequently metabolized, mainly in the
liver, into inactive morphine-3-glucaronide and the anal-
gesic morphine-6-glucaronide.6 These metabolites are
then excreted via the kidneys.7 This fast metabolism
leads to the need for repeated administration of mor-
phine, can result in low compliance, and can contribute
to the development of tolerance and dependence over
time.8 While several capsule forms9–11 have been devel-
oped to circumvent some of these problems, these tablets
often lead to abuse because they can be crushed into a
powder. Crushing these tablets causes a large amount of
morphine to be available at once, rather than slowly
releasing the drug over time, leading to greater psycho-
tropic effects and risk for abuse. Further, these extended
release tablets only modestly extend the analgesic effects
of morphine.12–14
Recently, we developed a new formulation of mor-
phine, called PolyMorphine, that could circumvent
these issues.15 PolyMorphine is efficiently synthesized
by chemically incorporating morphine in each repeat
unit through a poly(anhydride ester) backbone in a
three-step reaction.15 PolyMorphine was shown to be
analgesic for three days in naı¨ve mice using the tail-
flick assay, which is 20 times longer than free mor-
phine.15 What remains unclear is the extent to which
PolyMorphine works as an analgesic in chronic pain
models, how long its effects may last in these other
models, if it acts on the MOR in a manner similar to
free morphine, and what side effects may be associated
with PolyMorphine treatment. In this study,
PolyMorphine was evaluated for prolonged analgesia
potential in the spared nerve injury (SNI) model of
chronic pain.16 The SNI model has been shown to
induce long-lasting hypersensitivity in the ipsilateral
(injured) paw for up to nine weeks post-surgery.17,18
Herein, this chronic pain model was combined with sev-
eral measures of pain-like behaviors including von Frey
mechanosensory testing and the conditioned place
preference (CPP) assay. Based on the previously shown
extended analgesic effects of PolyMorphine, we hypothe-
sized that this polymer could block SNI-induced hyper-
sensitivity as measured by von Frey mechanosensory
testing for up to three days post-administration.
We also hypothesized that, if PolyMorphine works
through the activation of the MOR, then pretreatment
with naloxone, an MOR antagonist, would block the
analgesic-like effects of PolyMorphine. Since the effects
of PolyMorphine are ultimately due to the release of
free morphine monomers, we also predicted that
PolyMorphine would cause side effects similar to free
morphine such as hyperactivity19,20and constipation.21
Finally, we hypothesized that the long-lasting analgesic
effects of PolyMorphine would have the ability to block
the development of preference for a short-lasting anal-
gesic in the analgesic CPP assay.22–24
Materials and methods
PolyMorphine
The polymer was prepared according to previously pub-
lished procedures.15 Briefly, Morphine (1 in Figure 1,
1.00 g, 1 eq) was dissolved in anhydrous pyridine under
argon and stirred for 5min. Glutaric anhydride
(2, 3.97 g, 10 eq) was slowly added manually. The reac-
tion mixture was heated to 60C and stirred overnight.
Pyridine was azeotropically removed using toluene. The
brown paste obtained was washed 10 50mL with
dichloromethane (DCM) to remove the excess glutaric
acid. The final product was dried under vacuum at
room temperature. Morphine-based diacid (3, 0.18 g)
was acetylated by reacting with an excess of acetic
anhydride (36mL, Fisher, Fair Lawn, NJ). The reaction
mixture was stirred overnight at room temperature. The
excess acetic anhydride was removed under reduced pres-
sure. Yield: 0.16 g (89 %), orange paste. Morphine-based
monomer (4, 1.00 g) was polymerized by melt-condensa-
tion polymerization at 170C under constant vacuum
(<2mmHg) and constant stirring (100 r/min) using an
overhead mechanical stirrer (T-line laboratory stirrer,
Talboys Engineering Corp., Montrose, PA).
Polymerization continued until the mixture solidified
(30min). The product was cooled to room temperature
and dissolved in DCM (2mL). The polymer was preci-
pitated dropwise over excess diethyl ether (50mL) and
isolated by vacuum filtration. The product was dried
under vacuum at room temperature overnight. Yield:
0.70 g (70 %), tan solid.
Animals
All mouse protocols were in accordance with the guide-
lines of National Institutes of Health and approved by
the Animal Care and Use Committee of Duquesne
University (Pittsburgh, PA). All behavioral experiments
were performed on male C57Bl/6J mice. All mice were
8–10 weeks old when surgery and behavioral experimen-
tation took place. Animals were individually housed
after SNI surgery and kept on a 12-h light/dark cycle
from 7 a.m. to 7 p.m. with ad libitum access to both
food and water. Experiments were conducted during
the light cycle and performed by an experimenter who
was blinded to treatment and surgery type.
Surgery
SNI was performed as described previously.16
Mice were anesthetized with a 10:1 mixture of
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ketamine/xylazine at a dose of 10 mL/g. The hair overly-
ing the sciatic nerve was shaved and a 1 cm incision was
made parallel to the nerve. The sciatic nerve of the left
hind paw was exposed and two of the three branches
(tibial and common peroneal) were ligated. The third
branch of the sciatic nerve, the sural branch, was
not manipulated. Mice were allowed to recover on heat-
ing pads following surgery and a 2% lidocaine cream
was placed over the suture on the skin for acute pain
relief.
Drugs
Free morphine (morphine sulfate, Sigma) and
PolyMorphine were separately dissolved in a 5%
Cremophor EL saline solution at a dose of 10mg/kg
and 200mg/kg, respectively. Dosages of these com-
pounds were determined based on previously published
results.15,24 Naloxone (naloxone hydrochloride dihy-
drate, Sigma, St Louis, MO) was dissolved in 0.9%
saline at a dose of 1 or 10mg/kg. These doses were
based on previous publications.25,26 2-Methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP hydro-
chloride, Enzo Life Sciences) was dissolved in 0.9%
saline on the first day of drug pairing (day 2 of CPP)
at a dosage rate of 30mg/kg. The dose of MPEP was
determined using previously published CPP results with
MPEP in the SNI model.24
Drug administration
Morphine and PolyMorphine were both administered
intraperitoneally (IP) (10mg/kg and 200mg/kg, respect-
ively) in a volume of 100 mL. The vehicle control for both
morphine and PolyMorphine was 5% Cremophor EL
saline in a volume of 100 mL. In the naloxone experi-
ments, naloxone (1 or 10mg/kg) was administered sub-
cutaneously in a volume of 10 mL/g. The vehicle control
for naloxone was 0.9% saline in a volume of 10 mL/g.
In the CPP experiments, MPEP (30mg/kg) was admin-
istered IP in a volume of 20 mL 5min prior to behavioral
testing. The vehicle control for MPEP was 0.9% saline in
a volume of 20 mL. In von Frey testing, morphine,
PolyMorphine, or vehicle was injected once following
von Frey testing, which was completed one week after
surgery. In the naloxone von Frey experiment,
PolyMorphine was injected once following von Frey test-
ing one-week post-SNI and naloxone was administered
2 h prior to the beginning of each time point measured.
In the formalin test, naloxone (or saline) and morphine
(10mg/kg or saline) were administered 20min before the
injection of formalin (4% in a volume of 10 mL).
Spontaneous behavior (described below) was then ana-
lyzed for 60min. For the side effect experiments, mor-
phine, PolyMorphine, or vehicle was injected once
immediately prior to starting testing. In the CPP test,
morphine, PolyMorphine, or vehicle was injected in the
PolyMorphine
54
32
1
pyridine
60 °C, Ar
acetic anhydride
r.t.
170 °C
<2 mmHg
100 rpm
Figure 1. Synthesis of PolyMorphine (5). PolyMorphine 5 was synthesized from the reaction of morphine 1 and glutaric anhydride 2 via
ring opening followed by the acetylation of the diacid 3 and polymerization of the monomer 4 by melt condensation.
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evening on day 1 of CPP (several hours after baseline day
1 times were measured). MPEP and vehicle were given to
mice once a day for three consecutive days (on days 2, 3
and 4 of CPP, see below).
Behavioral testing
For mechanosensory studies with von Frey filaments,
mice underwent baseline testing to determine 50% with-
drawal thresholds using the up/down method.27,28
Animals were placed in Plexiglas boxes on a wire mesh
surface for 2 h prior to testing. Withdrawals were defined
as a full lifting of the foot off of the wire-mesh surface
when a filament was applied to the lateral edge of the
paw (area innervated by the sural branch of sciatic
nerve). Filaments ranging from 0.20mN to 25.1mN
(0.02–2.56 g) were used to determine the 50% withdrawal
thresholds. After baseline testing, mice underwent SNI.
One week after the surgery, mice were subjected to von
Frey testing again to observe withdrawal thresholds. All
animals were then given an injection of PolyMorphine
(200mg/kg), free morphine (10mg/kg), or vehicle. von
Frey testing was performed at 2 h and 4 h, as well as 1,
2, 3, 4, and 7 days after injection (corresponding to days
7, 8, 9, 10, and 14 days after surgery).This same proced-
ure was repeated for the mechanosensory testing with
PolyMorphine (200mg/kg) and naloxone (10mg/kg) stu-
dies, with naloxone or vehicle injections occurring 2 h
before each von Frey time point.
For spontaneous formalin behavior, animals were
placed in Plexiglas boxes on a clear Plexiglas surface
for 2 h prior to testing. After drug and formalin admin-
istration (see above), spontaneous pain-like behaviors
were recorded with a web-camera from beneath the ani-
mals for 60min and scored offline. Pain-like behaviors
were defined as the animal lifting, flinching, or biting the
injected paw.
For side effect behaviors, animals were injected with
PolyMorphine (200mg/kg), free morphine (10mg/kg),
or vehicle and individually housed for 3-h post-
injection. During the 3-h time period, animals were sub-
jected to sensory motor battery tests (platform test,
ledge test, pole test, and 60/90/inverted screen tests29)
at 30-min and 2-h post-injection. Also at the 2-h time
point, animals were placed in an open field box to
measure total distance traveled in a 10-min time
period. Activity was monitored with an overhead web
camera (Logitec Webcam Pro 9000) using AnyMaze
software (Stoelting Co., version 4.98). Total food and
water consumed after injection at the end of the 3h time
point were also measured. Finally, body temperature
(rectal) and total fecal boli deposited over the time
period were also measured. On days 1 to 3 post-
injection, mice underwent sensory motor battery and
open field again; food and water consumed and body
temperature/fecal boli were also measured over these
days as described for the injection day.
For spontaneous pain-like behavior, the analgesic
CPP (aCPP) assay was used as previously described.24,30
Mice first underwent SNI surgery. One week after the
surgery, mice were subjected to the five-day aCPP
assay, with the addition of a pretreatment that allowed
for the testing of long-lasting analgesic compounds. In
the aCPP assay, positive reinforcement is used to detect
non-evoked spontaneous pain where animals learn to
associate contextual cues (e.g. visual stripes on walls of
box) with the positive effects of a drug.22 The assay uses
a box with three different chambers: two outer chambers
that differ only in the visual patterns on the wall (hori-
zontal versus vertical black and white stripes) and a small
neutral chamber connecting the two outer chambers. On
the first day of the aCPP experiment (known as day 1 or
‘‘pre-conditioning’’), the mice are placed in the neutral
chamber and allowed to roam free between all three
chambers for 30min. No drugs are given to the mice
during this time. The total time that the animals spend
in each chamber is recorded with an overhead camera.
Six hours following baseline testing on day 1 animals are
given a pretreatment injection (100 mL) of PolyMorphine
(200mg/kg), free morphine (10mg/kg) or vehicle. On the
next three days of the experiment (days 2–4 or condition-
ing days), the mice receive a control vehicle injection
(20 mL of saline) in the morning and are restricted to
one of the outer chambers for 30min. In the afternoon,
the mice then receive an injection of the short-term anal-
gesic drug (20mL of 30mg/kg MPEP) and are placed in
the opposite outer chamber for 30min. Finally, on the
last day of the experiment (day 5 or post-conditioning),
the mice are placed with no injection in the neutral cham-
ber and allowed to roam free across the entire apparatus
for 30min, this exposure being a repeat of the testing
from day 1. The total time spent in each chamber is
recorded using two overhead web cameras (Logitec
Webcam Pro 9000 and Canon ZR420) and AnyMaze
software. Total times recorded on day 1 are compared
to those of day 5 to measure whether a preference for the
chambers developed. All behavioral testing was done
blinded to treatment and surgery.
Statistical analysis
Prism (version 6.0, GraphPad) was used for all behav-
ioral analysis. All data are shown as mean SEM.
Statistical significance was determined using t-tests or
two-way analysis of variance (ANOVA) followed by a
post hoc test. When analyzing von Frey, open field, and
constipation data, withdrawal thresholds, distance tra-
veled, and total fecal boli deposited were analyzed
using a two-way ANOVA followed by Bonferroni post
hoc tests, respectively. When analyzing formalin data,
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total amount of time exhibiting pain-like behaviors was
analyzed using a one-way ANOVA followed by a
Bonferroni post hoc test. When analyzing time difference
data from the CPP assay, a paired t-test was used.
Statistical significance was determined with a 95% con-
fidence interval (P< 0.05).
Results
PolyMorphine synthesis and degradation
into free morphine
Morphine diacid was synthesized via ring-opening reac-
tion between glutaric anhydride and morphine, followed
by the acetylation of the diacid and polymerization of
the monomer by melt condensation (Figure 1).
PolyMorphine was shown to hydrolytically degrade
in vitro at physiological conditions (37C and pH 7.4)
to free morphine in the following stages: hydrolytic
cleavage of the anhydride bonds to morphine-diacid 3
followed by hydrolysis of the ester bonds to yield free
morphine (Figure 2).
PolyMorphine blocks SNI-induced hypersensitivity
The ability of PolyMorphine to block SNI-induced
mechanical hypersensitivity was measured. Using von
Frey testing to determine 50% withdrawal thresholds,
a pretreatment of PolyMorphine (n¼ 8) reversed SNI-
induced hypersensitivity for up to 24-h post-injection
compared to vehicle-treated SNI animals (n¼ 8).
The reversal of SNI-induced hypersensitivity in mice
treated with regular morphine (n¼ 8) was gone after
2 h (Figure 3). These data demonstrate a significant
increase in PolyMorphine analgesia over time compared
to free morphine.
Naloxone blocks the analgesic-like effects of
PolyMorphine
To determine if PolyMorphine works through the same
molecular mechanism as free morphine, an MOR
antagonist (naloxone) was used to potentially inhibit
the analgesic effects of PolyMorphine. First, we deter-
mined a dose of naloxone sufficient to block free mor-
phine effects using the spontaneous formalin test.
Animals received a pretreatment of either vehicle or
morphine (10mg/kg) IP and vehicle or naloxone (1 or
10mg/kg) prior to formalin injection. Using this assay,
a dose of 10mg/kg of naloxone was found to be effect-
ive in fully blocking the analgesic effects of free mor-
phine (Figure 4(a)). Once this dosage was determined,
the ability of this dose of naloxone to block the anal-
gesic effects of PolyMorphine was measured. Using von
Frey testing to determine 50% withdrawal thresholds,
pretreatments of naloxone prior to each experimental
time point blocked the analgesic effects of
PolyMorphine in SNI animals with PolyMorphine
PolyMorphine
Morphine
Figure 2. Hydrolytic degradation of PolyMorphine 5.The anhydride linkages of polymer 5 are hydrolyzed first to generate diacid
intermediates (3), which are then further hydrolyzed to the final products, morphine (1) and adipic acid (7).
Lax et al. 5
(Figure 4(b)). Animals that received pretreatments of
vehicle showed the normal reversal of SNI-induced
hypersensitivity of up to 24-h post-PolyMorphine injec-
tion (Figure 4(b)). These data show that PolyMorphine
likely works through the MOR.
PolyMorphine causes constipation and increased
motor activity
Next, the side effects of free morphine and
PolyMorphine were compared. Animals were pretreated
with free morphine, PolyMorphine, or vehicle, and
motor deficiencies, constipation, hyperactivity, body
weight, body temperature, and food/water consumed
for up to three days post-injection were measured. No
differences were found between the groups in terms of
body weight, body temperature, or food/water consumed
at any of the time points measured (data not shown). For
constipation, animals treated with both free morphine
and PolyMorphine showed constipation for the first 3-
h post-injection (Figure 5(a)). This effect was not seen on
days 1 to 3 post-injection. Finally, hyperactivity was
measured using the open field test. Animals treated
with free morphine showed hyperactivity at 3-h post-
injection, while no hyperactivity was observed with
PolyMorphine at this time point (Figure 5(b)).
However, by one-day post-injection, PolyMorphine pre-
treated animals now showed hyperactivity whereas free
morphine pretreated animals did not. Overall, these data
show that PolyMorphine has some of the same side
effects as free morphine with subtle but potentially
important differences.
PolyMorphine blocks the development of preference
for MPEP in the analgesic CPP assay
For spontaneous pain-like behaviors, the analgesic CPP
assay was used. Typically in the analgesic CPP assay, a
short-lasting analgesic is repeatedly paired with a phys-
ical space to induce a conditioned preference response in
a mouse with on-going spontaneous pain.31 As
PolyMorphine is hypothesized to have a long-lasting
analgesic effect, PolyMorphine could not be used as the
normal pairing drug during the pairing days. Instead,
animals were given a pretreatment of the
PolyMorphine to determine if pretreatment blocked the
preference-inducing effect of a short-lasting analgesic,
MPEP. Pretreatment with PolyMorphine was compared
to pretreatment with free morphine or vehicle. Neither
free morphine nor vehicle pretreatment were hypothe-
sized to block MPEP CPP in SNI mice. Here, pretreat-
ments with saline caused mice to develop normal MPEP-
induced CPP (Figure 6(a)); SNI mice pretreated with
regular morphine also developed MPEP-induced CPP
(Figure 6(b)). However, pretreatment with
PolyMorphine blocked MPEP-induced CPP in SNI
mice (Figure 6(c)). Overall, these results support the
hypothesis that PolyMorphine causes analgesic-like
behavioral effects in both reflexive and spontaneous
pain-like behavior assays.
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Figure 3. PolyMorphine blocks SNI-induced hypersensitivity longer than free morphine. SNI mice treated with 200mg/kg of
PolyMorphine (n¼ 8) show reduced hypersensitivity compared to control SNI mice (n¼ 8) for up to 24 h after administration. SNI mice
treated with 10mg/kg of free morphine (n¼ 8) show reduced hypersensitivity compared to control SNI mice for only 2 h after admin-
istration. Two-way ANOVA, overall main effect of treatment, *P¼ 0.0153; overall main effect of time, ***P< 0.0001; Bonferroni post hoc
tests compared to vehicle (saline), *P< 0.05 and ***P< 0.0001. SNI: spared nerve injury.
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Discussion
Morphine and other mu opioid agonists have a long his-
tory in being used to treat both acute and chronic pain
conditions. There is an active push in the United States
to prepare compounds that could avoid the negative side
effects and short half-lives of most opioids. A majority of
the newer treatments using morphine have specifically
focused on trying to circumvent the problem of rapid
metabolism of the compound by focusing on extended-
release formulations of the drug.32 Here, for the first time,
we show the extended analgesic-like effects of a polymer
form of morphine, PolyMorphine, in a preclinical model
of chronic pain combined with behavioral testing in
mice. Using von Frey mechanosensory testing,
PolyMorphine was able to block SNI-induced hypersen-
sitivity for up to 24-h post-administration. This effect is in
contrast to the short-lived one of free morphine, wherein
the SNI-induced hypersensitivity is suppressed by mor-
phine for only 2-h post-administration. Mechanistically,
naloxone antagonism of MOR receptor blocked the
analgesic-like effects of PolyMorphine in SNI animals.
Additionally, PolyMorphine caused comparable side
effects of free morphine, such as constipation and hyper-
activity. Finally, in a non-evoked behavioral pain test, the
aCPP assay, PolyMorphine blocked the effects of the
short-term analgesic MPEP. This is again in contrast to
free morphine wherein normal MPEP-induced CPP
developed with free morphine pretreatment.
The use of opioids to treat pain has substantially
increased over the past few years, especially in the treat-
ment of non-cancer pain.33 This increase in use has coin-
cided with the development of extended release forms of
morphine that allow patients to be administered the
compounds less frequently. Some of the more commonly
used formulations that are available are Embeda, which
contains pellets of morphine sulfate with sequestered nal-
trexone34 and Kadian, which contains polymer coated
morphine sulfate pellets.32 Morphine has also been
incorporated into nanogels35 and liposomes36 in order
to increase the duration of its analgesic effects. The
main difference between these formulations and
PolyMorphine is that in these compounds, free morphine
is sequestered in a polymer coating, whereas in
PolyMorphine, free morphine is directly incorporated
into a polymer form. Despite these differences in
design, Embeda, Kadian, and Polymorphine have all
been found to release free morphine over time.37 Other
approaches have also been taken that attempt to limit
abuse liability by slowing the rate at which compounds
cross the blood–brain barrier (BBB) instead of extending
the release of drugs over time. One notable example is
NKTR-181, a compound that contains a five-ring mor-
phine-like scaffold bonded to a short-chain poly(ethylene
glycol).38,39 This functional group has previously been
shown to reduce oral bioavailability and transmission
rate across the BBB.40,41 Through this mechanism,
NKTR-181 provides analgesia in humans and is cur-
rently in Phase III clinical trials. However, this type of
formulation only circumvents potential abuse problems
and does not extend the analgesic effects of the com-
pound for longer than free opioids. Other attempts,
such as polymer formulations to extend analgesia and
prevent abuse, have tried using a polyurethane
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Figure 4. Naloxone blocks both free morphine and
PolyMorphine-induced analgesia. (a) Mice treated with 10mg/kg of
free morphine and 10mg/kg of naloxone (n¼ 6) show equal
amounts of pain-like behaviors compared to control mice (n¼ 12).
Mice treated with only 10mg/kg of morphine (n¼ 5) show sig-
nificantly less pain-like behaviors compared to the control and
morphine/naloxone (10mg/kg) groups. Naloxone (1mg/kg, n¼ 6)
was not a sufficient dose to block the analgesic effects of morphine.
(b) SNI mice treated with 200mg/kg of PolyMorphine and 10mg/kg
of naloxone (n¼ 6) prior to each post-injection time point
remained hypersensitive compared to SNI mice (n¼ 6) that
received PolyMorphine with vehicle injections. Formalin test—-
one-way ANOVA, overall main effect, ***P¼ 0.0007; Bonferroni
post hoc tests, *P< 0.05 and ***P< 0.0001. von Frey test—two-
way ANOVA, overall main effect of treatment, *P¼ 0.0211; overall
main effect of time, ***P< 0.0001; Bonferroni post hoc tests,
*P< 0.05 and ***P< 0.0001. SNI: spared nerve injury.
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backbone, but these formulations are problematic
because they lead to poor bioavailability due to their
inability to degrade in vivo.42 The poly(anhydride-
ester) backbone used in PolyMorphine can circumvent
many of the problems associated with other extended
release morphine formulations and has already been
used to make polymer formulations of NSAIDs,43 anti-
septics,44 and antioxidants.45 This specific polymer-type
formulation may be the key behind extending analgesia
while reducing abuse liability.
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Figure 6. PolyMorphine blocks MPEP-induced CPP in male SNI mice. (a) SNI mice pretreated with vehicle (n¼ 8) develop normal
preference for the MPEP-paired chamber. (b) SNI mice pretreated with 10mg/kg of free morphine (n¼ 8) also develop preference for the
MPEP-paired chamber. (c) SNI mice pretreated with PolyMorphine (n¼ 8) do not develop preference for the MPEP-paired chamber. Paired
t-tests,*P< 0.05. MPEP: 2-methyl-6-(phenylethynyl)pyridine.
(a) (b)
0
5
10
15
20
25
0
20
40
60
80PolyMorphine PolyMorphine
MorphineMorphine
SalineSaline
Total Distance - Open FieldFecal Boli Deposited - 3 hr period
Di
st
an
ce
 (m
)
Nu
m
be
r o
f B
ol
i
**
***
*
3 hr 1 day 2 day 3 day 2 hr 1 day 2 day 3 day
Post injection Post injection
Figure 5. PolyMorphine and free morphine induce constipation and hyperactivity. (a) Mice treated with 200mg/kg of PolyMorphine
(n¼ 6) or 10mg/kg of free morphine (n¼ 8) show constipation effects at 3-h post-injection compared to control animals (n¼ 6), with no
effects one to three days post-injection. (b) Mice treated with 200mg/kg of PolyMorphine (n¼ 6) show hyperactivity at one-day post-
injection with no effects 3-h or two to three days post-injection compared to vehicle-treated animals (n¼ 6). Mice treated with 10mg/kg of
free morphine (n¼ 8) show hyperactivity at 3-h post-injection with no effects one to three days post-injection compared to vehicle-treated
animals. Constipation—two-way ANOVA, overall main effect of treatment *P¼ 0.0385, overall main effect of time, ***P< 0.0001;
Bonferroni post hoc tests compared to vehicle, **P< 0.01. Hyperactivity—two-way ANOVA, overall main effect of treatment, P¼ 0.1275;
overall main effect of time, ***P< 0.0001; Bonferroni post hoc tests compared to vehicle, *P< 0.05 and ***P< 0.0001.
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Additionally, our results show that PolyMorphine has
the potential to be effective in providing extended anal-
gesia in animal models. Original testing with
PolyMorphine using the tail-flick assay showed that the
drug provided extended analgesic relief in mice, for up to
three days (20 times longer than free morphine).15 While
these results were promising, the tests were only done in
naı¨ve mice and only in one ‘‘experimenter-induced’’ pain
assay. Our results expand upon these data, showing that
PolyMorphine is effective in a classic model of chronic
neuropathic pain, SNI, providing similar reduction in
mechanical hypersensitivity compared to free morphine
initially along with extended relief up to 24 h after deliv-
ery. These extended analgesic results are similar to those
obtained in other rodent studies that looked at liposome-
encapsulated morphine in vivo. Liposome-encapsulated
morphine was shown to block the hypersensitivity asso-
ciated with male rats that had spinal nerve ligation in
thermal sensory testing36 and extend analgesic-like
effects in naı¨ve animals using the tail-flick test.46 Other
extended release formulas of morphine, however, such as
those produced using nanogels, only resulted in the
extension of analgesic effects for approximately 1 h
longer than that of free morphine when tested using
the hot-plate test in naı¨ve mice.35 Similarly, NKTR-
181, the five-ring morphine-like scaffold bonded to a
short-chain PEG produced analgesic-like effects for
only up to 4-h post-administration in the hot-plate test
in mice, this being similar to the effects of free opioids.39
In addition to this 24-h block in hypersensitivity with
PolyMorphine administration, we also showed that
PolyMorphine is effective in altering spontaneous pain-
like behaviors. In the classic aCPP assay, animals receive
a pain-inducing injury prior to testing. Following injury,
animals are conditioned to learn the effects of a short-
lasting analgesic agent. If animals receive relief from
their ongoing nociception, they will develop a preference
for the drug-paired chamber. We had previously shown
that three days of pairing with MPEP, an mGluR5
antagonist, alone induces preference in SNI but not
sham-operated mice.24 In our experiments here, we
used a pretreatment injection to determine if the
extended analgesic effects of PolyMorphine could block
the short-lasting analgesic effects of MPEP, such that
animals do not develop preference for the MPEP-
paired chamber. The MPEP results from vehicle-
pretreated mice were consistent with our previous data
with MPEP in SNI mice,24 wherein MPEP-induced CPP.
In a similar matter, pretreatment with free morphine also
resulted in mice developing a preference for MPEP. This
is because the short-term effects of the morphine wear off
before the pairing with MPEP occurs (e.g., approxi-
mately 20 h after morphine administration).
Conversely, animals pretreated with PolyMorphine did
not develop any preference for the MPEP-paired
chamber. This suggests that unlike free morphine,
PolyMorphine provided relief from the animal’s ongoing
nociception, such that when MPEP was administered,
the animals did not receive any additional relief during
the three days of pairing. These aCPP results, which sug-
gest PolyMorphine induces analgesic-like effects over a
three-day time period are in slight contrast to our von
Frey data that show the effects of PolyMorphine wearing
off by the two-day time point. One possible reason for
this difference could be the fundamentally different types
of pain that are being measured in each assay (i.e. experi-
menter-induced pain measured with von Frey testing
compared to spontaneous non-evoked pain measured
with aCPP). Our data suggest that PolyMorphine is
able to provide continuous ongoing relief to injured ani-
mals with spontaneous non-evoked pain for a signifi-
cantly longer period of time. The lack of preference for
MPEP in the PolyMorphine pretreatment group also
shows that there is no additive effect of the two drugs.
This observation is in contrast to studies that have
shown that coadministration of mGluR5 antagonists
and acute MOR agonists can generate enhanced
effects.47,48 If there had been some type of additive effects
where animals received greater relief from the combined
effects of MPEP and PolyMorphine, we would have pre-
dicted preference to still develop after PolyMorphine
pretreatment.
Our results, with both the experimenter-induced and
spontaneous pain-like behavior assays, suggest that
PolyMorphine has the potential to work significantly
better than other slow-release morphine formulations.
Further investigation with PolyMorphine is required to
determine if its extended analgesic-like effects are
observed when using female animals since all of the
testing done thus far has focused on males. However,
since female animals are known to respond to morphine
similar to males,24 we expect PolyMorphine to work in
females as well. Additional work investigating the poten-
tial addictive nature of PolyMorphine will also need
to be completed. To our knowledge, no studies have
investigated the self-administration rates of polymers of
opioids. However, since the morphine is sequestered into
a polymer that slowly releases free morphine, animals
would not be predicted to self-administer.
Mechanistically, we demonstrated that PolyMorphine
most likely works through the same pathway as free
morphine. Since PolyMorphine was previously shown
to generate free morphine in vivo,15 it was expected
that the free morphine generated would also work
through MOR activation. Here, we were able to reverse
PolyMorphine-induced analgesia with a pretreatment of
the drug naloxone. Naloxone is a selective antagonist of
the MOR and has been extremely valuable for investigat-
ing the opioid actions of compounds preclinically.
Naloxone has 9 times greater affinity for mu compared
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to the kappa opioid receptor and 60 times greater affinity
for mu compared to the delta opioid receptor.49 Unlike
other selective antagonists (such as b-FNA and norBNI)
whose actions can last for weeks after the elimination of
the drug, naloxone acts as a simple competitive antagon-
ist, whose effects are much shorter and reversible.50
Thus, our results show that PolyMorphine, just like
free morphine, likely works through MOR activation.
Finally, PolyMorphine was shown to have a com-
parable side effect profile to free morphine. With the
doses of PolyMorphine (200mg/kg) and free morphine
(10mg/kg) used, no motor deficiencies, ataxia, or hypo-
thermia were observed. This result is not surprising how-
ever, since this dose of morphine may be too low to
observe these particular effects.19 It also suggests that
when PolyMorphine is metabolized into free morphine
in vivo, the amount of free morphine in the animal’s
bloodstream remains at or below the amount when free
morphine is administered at the rate of 10mg/kg.
However, further testing of blood concentrations of free
morphine in animals treated with PolyMorphine would be
needed to confirm this hypothesis. Other side effects of
morphine and related compounds include opioid-induced
constipation21,51 due to the presence of the MOR in the
colon. Animals treated with both PolyMorphine and free
morphine develop this acute side effect 3 h after adminis-
tration. Similarly, opioids are known to stimulate motor
activity.19,20 Hyperactivity was seen at different times post-
administration between free morphine (3h) and
PolyMorphine (24 h). This lack of increase in the magni-
tude of side effects with an extension in analgesic-like
properties has been shown in other animal models with
liposome deliveries of morphine.52,53
The varying times at which each of the different side
effects are seen may provide some insight into how
PolyMorphine is distributed and metabolized after injec-
tion. Our data suggest that when PolyMorphine is first
administered, some of the first free morphine generated
in the bloodstream from polymer breakdown remains in
the periphery and immediately binds with the MORs in
the gastrointestinal tract54 causing constipation. The
delay in locomotor hyperactivity with PolyMorphine
shows that there may not be enough free morphine pre-
sent in the CNS until 24 h after injection to stimulate the
dopaminergic locomotor system.55 On the other hand,
PolyMorphine induces both acute (2 h and 4 h) and
extended (24 h) analgesic effects. These data suggest
that enough free morphine is cleaved off the polymer
quickly and for an extended period of time, where it
can act at analgesic targets in the periphery and CNS.
With regular morphine, since no breakdown of a poly-
mer is needed to generate free morphine, sufficient drug
is immediately available to induce analgesia and all
of the side effects immediately after administration,
and none of the effects persist longer than 3 h after
injection. These data suggest the potential for slightly
altered release kinetics of PolyMorphine after injection
on side effect profiles.
Overall, mice that receive an injection of
PolyMorphine have a reversal of SNI-induced hypersen-
sitivity for up to 24-h post-administration and this effect
is blocked by naloxone. PolyMorphine also has a similar
side effect profile to free opioids. Finally, SNI animals do
not develop preference for the short-term analgesic
MPEP when given a PolyMorphine pretreatment, pre-
sumably because of PolyMorphine’s long-lasting effects.
These effects are in contrast to those of free morphine,
whose effects are no longer observed after a couple of
hours. Our results demonstrate that the poly(anhydride-
ester) backbone in the synthesis of an extended-release
morphine may have a promising future in the treatment
of chronic pain conditions. A valuable goal is to find an
opioid that can be administered in the clinic and last
for weeks or longer to treat persistent acute pain (e.g.,
following major trauma), thus preventing the need for
distribution and potential abuse. While PolyMorphine
does not yet achieve this level of efficacy, future formu-
lations may represent a step in the right direction for
battling the current opioid epidemic.
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